Opportunity Information: Apply for PA 09 226
Apply for PA 09 226
- The National Institutes of Health in the food and nutrition health income security and social services sector is offering a public funding opportunity titled "Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Jul 2, 2009 and posted on Jul 2, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments Native American tribal governments (Federally recognized) Private institutions of higher education County governments Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Independent school districts Special district governments For profit organizations other than small businesses Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH Program Announcement PA 09-226, titled "Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01)," supports research aimed at improving understanding and care of congenital obstructive uropathy, a major contributor to chronic kidney disease and end stage renal disease in infants and children. The central problem this opportunity tries to address is that, despite the clinical impact of congenital urinary tract obstruction, its underlying biology and disease mechanisms are still not well defined. As a result, clinicians face persistent uncertainty about how best to detect these conditions early, how to predict outcomes for individual patients, and how to choose the most effective treatment approach. The announcement emphasizes that major gaps remain around the real benefits and risks of early fetal detection and neonatal intervention, the long-term consequences of conservative management (often described as watchful waiting), and the comparative effectiveness of different surgical strategies. It also highlights the lack of agreement on when surgery is truly indicated and what timing leads to the best kidney and urinary outcomes over a child s lifetime.
This funding opportunity is sponsored by two NIH Institutes, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), reflecting both the kidney disease burden and the pediatric and developmental dimensions of the disorder. The research areas encouraged by the announcement are broad and intentionally span both basic science and clinical investigation. Examples of the kinds of work the FOA seeks include developing objective prognostic markers that can better predict which fetuses or infants will progress to significant kidney damage, studying genetic contributors and determinants that may explain why obstruction develops or why some children have worse outcomes than others, creating and validating reliable animal models that more faithfully reproduce the human condition, and performing longer-term evaluations of treatment strategies to determine which approaches actually improve kidney function, urinary tract health, and overall outcomes over time. The underlying theme is to reduce controversy and variability in care by producing stronger evidence about disease mechanisms and treatment effectiveness, especially evidence that can guide real-world clinical decisions.
The mechanism of support is the NIH Research Project Grant (R01), meaning the program is designed for discrete, hypothesis-driven projects with well-defined aims, and it is flexible enough to support a wide range of experimental and clinical study designs. The announcement does not set a fixed award size or a fixed number of awards. Instead, it notes that budgets and project periods may vary depending on the nature and scope of the proposed research, and that the total number of funded projects and overall dollars awarded depend on the quality, duration, and costs of the applications received, as well as available funds and program priorities.
From an administrative standpoint, this is a discretionary grant opportunity offered by the National Institutes of Health. It is associated with CFDA numbers 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.865 (Child Health and Human Development Extramural Research). There is no cost sharing or matching requirement. The opportunity was posted July 2, 2009, with an original and final closing date of September 7, 2012, and it was archived October 8, 2012. While it is no longer open, the summary captures the intent and research scope that guided the solicitation during its active period.
Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants listed include state, county, city or township, and special district governments; federally recognized tribal governments and other tribal organizations; public and private institutions of higher education; nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities, excluding higher education institutions where specified); for-profit organizations (including small businesses and other for-profit entities); independent school districts; public housing authorities and Indian housing authorities; and a range of other institution types noted in the eligibility clarification. Additional eligible applicants explicitly include Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based and community-based organizations, eligible federal agencies, U.S. territories and possessions, regional organizations, and foreign (non-U.S.) entities. In practical terms, the FOA was designed to draw strong applications from diverse research settings, including academic medical centers, pediatric hospitals, translational research groups, and basic science laboratories, as long as the proposed work directly addresses major uncertainties in congenital urinary tract obstruction.
The full announcement was made available through NIH, with a link provided to the NIH grants guide (PA 09-226). For technical issues accessing the announcement, NIH listed the NIH Office of Extramural Research webmaster contact (FBOWebmaster@od.nih.gov) for support with access or linking problems.
Frequently Asked Questions (FAQs)
What is the title and identifier of this NIH funding opportunity?
This program announcement is NIH PA 09-226, titled "Basic and Clinical Studies of Congenital Urinary Tract Obstruction (R01)."
What health problem is this opportunity focused on?
The opportunity focuses on congenital urinary tract obstruction (also described as congenital obstructive uropathy), which is described as a major contributor to chronic kidney disease and end stage renal disease in infants and children.
Why did NIH issue this program announcement?
The announcement highlights that, despite the clinical impact of congenital urinary tract obstruction, the underlying biology and disease mechanisms are still not well defined. This creates ongoing uncertainty for clinicians about early detection, predicting outcomes for individual patients, and selecting the most effective treatment approach.
What central research gap is the FOA trying to address?
The core gap is limited understanding of the biology and mechanisms of congenital urinary tract obstruction, along with insufficient evidence to guide key clinical decisions such as early detection strategies, prognosis, and treatment selection.
What kinds of clinical uncertainties does the FOA emphasize?
The FOA specifically points to unresolved questions about the benefits and risks of early fetal detection and neonatal intervention, the long-term consequences of conservative management (watchful waiting), and the comparative effectiveness of different surgical strategies.
Does the announcement address questions about when surgery should be done?
Yes. It notes a lack of agreement on when surgery is truly indicated and what timing leads to the best kidney and urinary outcomes over a child's lifetime.
Which NIH Institutes sponsor this program announcement?
The opportunity is sponsored by two NIH Institutes: the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Why are both NIDDK and NICHD involved?
The sponsorship reflects both the kidney disease burden (NIDDK) and the pediatric and developmental dimensions of the disorder (NICHD), as described in the announcement summary.
What is the grant mechanism used for this opportunity?
The mechanism of support is the NIH Research Project Grant (R01).
What does it mean that this is an R01 opportunity?
The announcement describes the R01 as supporting discrete, hypothesis-driven projects with well-defined aims, and notes that it is flexible enough to support a wide range of experimental and clinical study designs.
Is the scope limited to basic science, or can it include clinical studies?
The scope is intentionally broad and spans both basic science and clinical investigation.
What types of research projects are encouraged under this FOA?
Examples listed include: developing objective prognostic markers to predict progression to significant kidney damage; studying genetic contributors and determinants related to why obstruction develops or why outcomes differ; creating and validating reliable animal models that better reproduce the human condition; and conducting longer-term evaluations of treatment strategies to determine which approaches improve kidney function, urinary tract health, and overall outcomes over time.
Does the FOA encourage work on prognostic markers?
Yes. The announcement specifically encourages developing objective prognostic markers that can better predict which fetuses or infants will progress to significant kidney damage.
Does the FOA encourage research on genetics?
Yes. It encourages studying genetic contributors and determinants that may explain why obstruction develops or why some children have worse outcomes than others.
Are animal models within scope for this funding opportunity?
Yes. The FOA includes creating and validating reliable animal models that more faithfully reproduce the human condition as an example of encouraged research.
Does the FOA prioritize long-term outcome studies of treatments?
Yes. It highlights longer-term evaluations of treatment strategies to determine which approaches improve outcomes over time, including kidney function and urinary tract health.
What is the broader goal of the research encouraged by this announcement?
The underlying theme is to reduce controversy and variability in care by producing stronger evidence about disease mechanisms and treatment effectiveness, particularly evidence that can guide real-world clinical decisions.
Is a specific award size or number of awards specified?
No. The announcement does not set a fixed award size or a fixed number of awards.
How are budgets and project periods handled under this FOA?
Budgets and project periods may vary depending on the nature and scope of the proposed research.
What determines how many projects get funded and how much money is awarded overall?
The announcement indicates that the number of funded projects and total dollars awarded depend on the quality, duration, and costs of the applications received, as well as available funds and program priorities.
Is this a mandatory or discretionary funding opportunity?
It is described as a discretionary grant opportunity offered by the National Institutes of Health.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and CFDA 93.865 (Child Health and Human Development Extramural Research).
Is cost sharing or matching required?
No. The announcement states there is no cost sharing or matching requirement.
When was this opportunity posted, and what were the closing dates?
It was posted on July 2, 2009. The original and final closing date was September 7, 2012.
Is this funding opportunity still open?
No. It was archived on October 8, 2012, and is no longer open.
Who was eligible to apply?
Eligibility is broad and includes many types of domestic and non-domestic organizations, including various levels of government, tribal governments and organizations, public and private institutions of higher education, nonprofit organizations, for-profit organizations (including small businesses), independent school districts, public housing authorities and Indian housing authorities, and other institution types referenced in the eligibility clarification.
Are foreign (non-U.S.) organizations eligible?
Yes. The eligibility list explicitly includes foreign (non-U.S.) entities.
Are U.S. territories and possessions included as eligible applicants?
Yes. The eligibility information explicitly includes U.S. territories and possessions.
Are specific institution categories (such as HBCUs or HSIs) mentioned as eligible?
Yes. The announcement explicitly lists Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities, and Tribally Controlled Colleges and Universities among eligible applicants.
Are faith-based or community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly included in the eligibility list.
Are federal agencies eligible to apply?
Yes. The eligibility list explicitly includes eligible federal agencies.
What types of research settings did the FOA aim to attract?
The summary indicates the FOA was designed to draw strong applications from diverse research settings, including academic medical centers, pediatric hospitals, translational research groups, and basic science laboratories, provided the work directly addresses major uncertainties in congenital urinary tract obstruction.
Where could applicants find the full announcement?
The full announcement was made available through NIH, with a link provided to the NIH grants guide for PA 09-226.
Who should be contacted for technical problems accessing the announcement link?
For technical issues accessing the announcement, NIH listed the NIH Office of Extramural Research webmaster contact: FBOWebmaster@od.nih.gov.
Browse more opportunities from the same category: Food and Nutrition Health Income Security and Social Services
Next opportunity: Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellows in Nursing Research (F31)
Previous opportunity: Recovery Act Broadband Technology Opportunities Program (BTOP)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 226
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 226) also looked into and applied for these:
| Funding Opportunity |
|---|
| Small Business Innovation Research to Develop New Therapeutics and Monitoring Technologies for Type 1 Diabetes (T1D). Towards an Artificial Pancreas (SBIR) (R43/R44) Apply for RFA DK 10 008 Funding Number: RFA DK 10 008 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R01) Apply for PAR 10 230 Funding Number: PAR 10 230 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Innovative Therapies and Tools for Screenable Disorders in Newborns (R21) Apply for PAR 10 232 Funding Number: PAR 10 232 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $200,000 |
| A GenitoUrinary Development Molecular Anatomy Project (GUDMAP) Database and Website (U01) Apply for RFA DK 10 005 Funding Number: RFA DK 10 005 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Lifestyle Interventions in Overweight and Obese Pregnant Women Consortium (U01) Apply for RFA DK 10 014 Funding Number: RFA DK 10 014 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: Case Dependent |
| Feasibility Studies for Clinical Trials in Type 1 Diabetes (R03) Apply for RFA DK 11 007 Funding Number: RFA DK 11 007 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $50,000 |
| Clinical Trial Planning Grants in Type 1 Diabetes (R34) Apply for RFA DK 11 010 Funding Number: RFA DK 11 010 Agency: National Institutes of Health Category: Food and Nutrition Health Income Security and Social Services Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 226", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.